Nemera and Therakind have announced a strategic partnership to advance and industrialize the DriDose dry powder intranasal technology.
This strategic partnership brings together Nemera’s know-how in combination product device development and industrialization, with Therakind’s experience in developing and delivering innovative medicines to patients.
The DriDose platform – a dry powder intranasal device portfolio developed by Therakind – perfectly complements Nemera’s existing range of nasal delivery solutions, which currently supports liquid formulations. Nemera, a global leader in design, development and manufacturing of drug delivery device solutions, broadens its innovative nasal portfolio to include a complete dry powder delivery platform, further enhancing its end-to-end offering for pharmaceutical and biotechnology partners.
Therakind, a UK-based pharmaceutical company with a strong track record in transitioning products from development to regulatory approval is consolidating its core business of drug device combination product development. Therakind will continue to leverage the DriDose platform to enhance patient outcomes both with internal projects and in collaboration with third parties.
Dr Susan Conroy, CEO of Therakind said, “We are delighted to partner with Nemera, known for its expertise in drug delivery solutions and novel device industrialization. As a market leader in devices with a global presence, Nemera is an ideal partner for the DriDose portfolio industrialization and expansion.”
Dimitri Grasswill, vice president of Nemera’s Ear, Nose and Throat business added, “We are thrilled to partner with Therakind and benefit from their strong track record in pharmaceutical development and regulatory approvals. The innovative DriDose technology will open Nemera to new therapeutic areas in nasal drug delivery and will significantly improve patients’ lives – it perfectly complements our product portfolio especially by targeting unmet needs in systemic and non-systemic treatments.”
Together, Nemera and Therakind will accelerate the development of next generation nasal therapies, offering pharmaceutical partners expanded formulation expertise and innovative, patient friendly devices.
